title: Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
abstract: Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.
authors.affiliation: Hospital Clínic, Barcelona, Spain.
authors.forename: Esteban
authors.initials: E
authors.lastname: Martínez
authors.forename: Juan A
authors.initials: JA
authors.lastname: Arnaiz
authors.forename: Daniel
authors.initials: D
authors.lastname: Podzamczer
authors.forename: David
authors.initials: D
authors.lastname: Dalmau
authors.forename: Esteban
authors.initials: E
authors.lastname: Ribera
authors.forename: Pere
authors.initials: P
authors.lastname: Domingo
authors.forename: Hernando
authors.initials: H
authors.lastname: Knobel
authors.forename: Maria
authors.initials: M
authors.lastname: Leyes
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Luís
authors.initials: L
authors.lastname: Force
authors.forename: Elisa
authors.initials: E
authors.lastname: de Lazzari
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
mesh_terms: D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D048588:Benzoxazines / Q000627:therapeutic use; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D019829:Nevirapine / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D000099227:Abacavir
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019829:Nevirapine; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz